Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy
AssigneeTel Aviv University Future Technology Development L.P.
InventorsRimona Margalit, Dan Peer
Life of this patent
Estimating the term…
Abstract
Lipidated glycosaminoglycan particles, prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid, are used to encapsulate drugs for use in the treatment of pathological conditions in an animal.
Claims24
A method for treating an animal suffering from a cancer, wherein the cancer cells have a glycosaminoglycan recognition site comprising administering to said animal an effective amount of an anticancer drug for treating said cancer encapsulated in a water-insoluble lipidated glycosaminoglycan particle in the form of a sphere with the glycosaminoglycan portion of the particle forming a shell on the outside and the lipid portion of the particle forming the inside, without the presence of liposome, said particle comprising the reaction product of at least one glycosaminoglycan with at least one lipid having a primary amino group, wherein the ratio of said at least one lipid having a primary amino group to said at least one glycosaminoglycan is in the range of 1:1 and 5:1 to 20:1 and said at least one glycosaminoglycan has a molecular weight within the range of about 1×105 to about 1×107 daltons.
A method for targeted delivery of a biologically active material to a cell having a glycosaminoglycan recognition site, comprising administering a bioactive agent encapsulated in a water-insoluble lipidated glycosaminoglycan particle in the form of a sphere with the glycosaminoglycan portion of the particle forming a shell on the outside and the lipid portion of the particle forming the inside, without the presence of liposome, said particle comprising the reaction product of at least one glycosaminoglycan with at least one lipid having a primary amino group,
- wherein:
- the glycosaminoglycan in the glycosaminoglycan particle corresponds to the glycosaminoglycan recognition site on the cell to which the biologically active material is to be delivered;
- the ratio of said at least one lipid having a primary amino group to said at least one glycosaminoglycan is in the range of 1:1 and 5:1 to 20:1;
- and
- said at least one glycosaminoglycan has a molecular weight within the range of about 1×105 to about 1×107 daltons.
Dependencies are inferred from the claim text.